AIM ImmunoTech (AIM) vs PharmaCyte Biotech (PMCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($7.2 million vs $4.3 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | PMCB |
|---|---|---|
| Share price | $0.1796 | $0.3974 |
| Market cap | $7.17M | $4.27M |
| 1-day change | -1.75% | -2.02% |
| EPS (TTM) | $-2.98 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $1.51 |
| 52-week low | $0.17 | $0.3339 |
| Distance from 52-week high | -93.57% | -73.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +2266.37% | — |
| Average volume | 4.70M | 205.72K |
| Shares outstanding | 39.89M | 10.74M |
| Employees | 19 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees
AIM vs PMCB FAQ
Which is bigger, AIM ImmunoTech or PharmaCyte Biotech?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $7.17M compared with $4.27M for PharmaCyte Biotech (PMCB).
Are AIM ImmunoTech and PharmaCyte Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.